Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.
|Number of pages||3|
|Journal||Clinical and Experimental Rheumatology|
|Publication status||Published - Jul 1 2020|
- Mevalonate kinase deficiency
ASJC Scopus subject areas
- Immunology and Allergy